摘要
目的观察普瑞巴林联合塞来昔布治疗膝骨关节炎(KOA)疼痛的临床效果。方法选择本院2017年1月~2019年7月就诊的84例KOA患者作为研究对象,根据随机数字表法分为两组,对照组(n=42)仅予以塞来昔布胶囊口服治疗,观察组(n=42)在对照组基础上加用普瑞巴林胶囊口服治疗,两组患者均连续治疗8周。采用视觉模拟评分量表(VAS)、西安大略与麦克马斯特大学骨关节炎指数(WOMAC)对两组患者治疗前及治疗第1、4、8周的膝关节疼痛情况、膝关节功能进行评估,记录两组患者治疗期间出现的恶心、呕吐、头晕等不良反应。结果两组患者治疗前VAS评分比较,差异无统计学意义(P>0.05),两组患者治疗第1、4、8周时VAS评分均低于治疗前,观察组患者治疗第1、4、8周时VAS评分均低于对照组,差异有统计学意义(P<0.05);两组患者治疗前WOMAC评分比较,差异无统计学意义(P>0.05),两组患者治疗第1、4、8周时WOMAC评分均低于治疗前,观察组患者治疗第1、4、8周时WOMAC评分均低于对照组,差异有统计学意义(P<0.05);观察组患者不良反应总发生率(11.90%)与对照组(9.52%)比较,差异无统计学意义(P>0.05)。结论普瑞巴林联合塞来昔布可明显减轻KOA疼痛,改善患者膝关节功能,且具有较高的安全性。
Objective To observe the clinical efficacy of pregabalin combined with celecoxib in the treatment of knee osteoarthritis(KOA)pain.Methods A total of 84 patients with KOA admitted to our hospital from January 2017 to July 2019 were selected as the research objects,and they were divided into two groups according to the random number table method.The control group(n=42)was treated with orally administrated celecoxib capsule only,while the observation group(n=42)was treated with orally administrated pregabalin capsule on the basis of the control group.Both groups of patients were treated continuously for 8 weeks.The visual analogue scale(VAS)and the osteoarthritis index of the University of Western Ontario and McMaster,Canada(WOMAC)were applied to evaluate the knee joint pain and knee joint function before treatment and at the 1st,4th and 8th week of treatment.Meanwhile,the adverse reactions(ADRs)such as nausea,vomiting and dizziness of the two groups of patients during treatment were recorded.Results There was no statistically significant difference in VAS scores between the two groups of patients before treatment(P>0.05).VAS scores of the two groups of patients at the 1st,4th and 8th weeks during treatment were all lower than those before treatment,and VAS scores of the observation group of patients at the 1st,4th and 8th weeks during treatment were all lower than those of the control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in WOMAC scores between the two groups of patients before treatment(P>0.05).The WOMAC scores of the two groups of patients at the 1st,4th and 8th weeks during treatment were all lower than those before treatment,and WOMAC scores of the observation group of patients at the 1st,4th and 8th weeks during treatment were all lower than those of the control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the total incidences of ADRs between 11.90%in the observation group and 9.52%in the control group(P>0.05).Conclusion Pregabalin combined with celecoxib can significantly relieve the pain of KOA,and improve the knee joint function of patients.Meanwhile,they have relatively high safety.
作者
高贤琼
GAO Xianqiong(Department of Medical Equipment,Inpatient Division,Dispensary for Western Medicine,Egang Hospital of Ezhou City in Hubei Province,Hubei,Ezhou 436000,China)
出处
《中国医药科学》
2020年第22期68-70,74,共4页
China Medicine And Pharmacy
